Novocure EF-36/Keynote B36

Condition: Lung

Lung

NON-SMALL CELL LUNG CANCER (NSCLC): 2 Studies 

Novocure EF-36/Keynote B36 – A Pilot, single arm, open-label study of Tumor Treating Fields (TTFields, 150 kHz) concomitant with Pembrolizumab for First Line Treatment of Advanced Metastatic Intrathoracic NSCLC. 

Who’s Eligible:  

• Histologically or cytologically confirmed de novo diagnosis of Stage III/Metastatic intrathoracic NSCLC (cannot have EGFR activating mutation or ALK translocation). Also, has a PD-L1 positive tumor (TPS ≥ 1%). 
• No prior treatments for NSCLC. Palliative treatment is allowed. 
• Age 22+ 
• Have no history of prior malignancy EXCEPT basal cell carcinoma, superficial bladder cancer, squamous cell carcinoma, or in situ cervical cancer, or undergone potentially curative therapy with no evidence of disease recurrence for 5 years since initiation of said therapy. 

Lung

Regeneron R2810-ONC-2045 – A Phase 1/2 Study Of Cemiplimab (Anti-PD-1 Antibody) In Combination With BNT116 (FixVac Lung) Versus Cemiplimab Monotherapy In First-Line Treatment Of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) With Tumors Expressing PD-L1 ≥50% 

Who’s Eligible:  

• Age 18+  
• Patients with Non-Squamous or Squamous histology with Stage IIIB/IIIC disease who are not candidates for surgical resection or definitive chemoradiation.  
• Expression of PD-L1 in  ≥ 50% of tumor cells. 

If you would like more information please contact clinical trials research coordinator at DJL Research in Charlotte 704-247-9179, x-207